Kevin B. Kim

发表

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.

J. Sosman, A. Ribas, P. Hwu, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma

Kevin B. Kim, D. Char, M. Kashani-Sabet, 2022, Cancer biotherapy & radiopharmaceuticals.

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

K. Flaherty, J. Sosman, I. Puzanov, 2012, The New England journal of medicine.

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

K. Flaherty, R. Kurzrock, N. Le, 2012, The Lancet. Oncology.

Inhibition of mutated, activated BRAF in metastatic melanoma.

K. Flaherty, J. Sosman, A. Ribas, 2010, The New England journal of medicine.

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.

A. D. Van den Abbeele, A. Giobbie-Hurder, K. Flaherty, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity.

J. Sosman, G. Schwartz, M. Postow, 2014 .

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Kam Y. J. Zhang, K. Flaherty, J. Sosman, 2010, Nature.

Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.

Richard J. Lee, A. Lazar, Michelle D. Williams, 2013, Thyroid : official journal of the American Thyroid Association.

A phase II study of gefitinib in patients with metastatic melanoma.

S. Patel, P. Hwu, Kevin B. Kim, 2009, Melanoma research.

A first‐in‐human phase I, multicenter, open‐label, dose‐escalation study of the oral RAF/VEGFR‐2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status

Benjamin Izar, K. Flaherty, R. Dummer, 2017, Cancer medicine.

Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma

Michael A. Davies, Chaan S. Ng, Roland L. Bassett, 2012, Clinical Cancer Research.

Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib

M. Ross, A. Lazar, P. Hwu, 2008, Nature Clinical Practice Oncology.

The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma

M. Gulley, Douglas B. Johnson, R. Alkallas, 2022, BMC cancer.

Drug responses are conserved across patient-derived xenograft models of melanoma leading to identification of novel drug combination therapies

L. Soroceanu, A. Dar, Kevin B. Kim, 2019, British Journal of Cancer.

Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon‐V600 mutations in cutaneous melanoma patients

J. McQuade, J. Wargo, A. Lazar, 2017, Cancer.

Clinical responses to selumetinib (AZD6244; ARRY‐142886)‐based combination therapy stratified by gene mutations in patients with metastatic melanoma

A. Lazar, S. Patel, M. Davies, 2013, Cancer.

Eruptive Squamous Cell Carcinomas after Vemurafenib Therapy

K. Tsai, F. Khan, Kevin B. Kim, 2013, Journal of cutaneous medicine and surgery.

Biochemotherapy in patients with advanced head and neck mucosal melanoma

M. Ballo, P. Hwu, Kevin B. Kim, 2008, Head & neck.

Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment

P. Hwu, G. Lizée, Kevin B. Kim, 2008, Melanoma research.

Activity of the MEK Inhibitor Trametinib (GSK1120212) in Advanced Melanoma in a Phase I, Dose-escalation Trial

K. Flaherty, R. Kurzrock, N. Le, 2014 .

Is there a role for targeting vascular endothelial growth factor/receptor axis in the treatment of patients with metastatic melanoma?

Kevin B. Kim, 2013, Cancer.

Pharmacokinetics and Safety of Marqibo (Vincristine Sulfate Liposomes Injection) in Cancer Patients With Impaired Liver Function

M. Davies, P. Hwu, J. Homsi, 2011, Journal of clinical pharmacology.

Identification of a novel synthetic triterpenoid, methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate, that potently induces caspase-mediated apoptosis in human lung cancer cells.

M. Sporn, R. Lotan, W. Hong, 2002, Molecular cancer therapeutics.

The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma

P. Hwu, L. Camacho, Kevin B. Kim, 2010, Melanoma research.

Predictive Biomarkers and Personalized Medicine Impact of Clinical and Pathologic Features on Tumor-Infiltrating Lymphocyte Expansion from Surgically Excised Melanoma Metastases for Adoptive T-cell Therapy

Jeffrey E. Lee, M. Ross, A. Lucci, 2011 .

Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses.

C. Ng, E. Ashton, F. Kelcz, 2010, AJR. American journal of roentgenology.

Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, GleevecTM)

Kevin B. Kim, D. Ivan, A. H. Diwan, 2006, Journal of cutaneous pathology.

Updated overall survival (OS) results for BRF113220, a phase I-II study of dabrafenib alone versus combined dabrafenib and trametinib in patients with BRAF V600 metastatic melanoma (MM).

K. Flaherty, J. Sosman, I. Puzanov, 2015 .

Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM).

K. Flaherty, J. Sosman, I. Puzanov, 2014 .

Impact of comorbidities on overall survival of high-risk and advanced melanoma.

M. Suarez‐Almazor, J. Gershenwald, Kevin B. Kim, 2012 .

Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report.

Kevin B. Kim, B. Guadagnolo, D. Sanders, 2013, Melanoma research.

Recent advances in the management of squamous cell carcinoma of the head and neck

F. Khuri, Kevin B. Kim, D. Shin, 2001, Expert review of anticancer therapy.

Significant Clinical Response to a MEK Inhibitor Therapy in a Patient With Metastatic Melanoma Harboring an RAF1 Fusion.

M. Singer, Siraj M. Ali, Kevin B. Kim, 2018, JCO precision oncology.

Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanoma

N. Salomonis, L. Soroceanu, A. Dar, 2022, Proceedings of the National Academy of Sciences of the United States of America.

A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma

Dae Hyun Kim, S. Patel, P. Hwu, 2017, Cancer Immunology, Immunotherapy.

Long term Survival with CTLA-4 blockade Using Tremelimumab

A. Ribas, L. Camacho, Kevin B. Kim, 2016 .

Immunohistochemical Expression of Hormone Receptors in Melanoma of Pregnant Women, Nonpregnant Women, and Men

P. Fox, Kevin B. Kim, J. Myers, 2014, The American Journal of dermatopathology.

Diffuse granulomatous panniculitis associated with anti PD-1 antibody therapy

Kevin B. Kim, M. Kashani-Sabet, S. Leong, 2017, JAAD case reports.

Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma.

Jeffrey E. Lee, M. Ross, M. Ballo, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma

Kevin B. Kim, Mandy S Harting, 2004, Melanoma research.

Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)

M. Atkins, F. Hodi, M. Smylie, 2020, Melanoma research.

Early FDG-PET responses to PLX4032 in BRAF-mutant advanced melanoma.

K. Flaherty, J. Sosman, A. Ribas, 2010 .

Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy

A. Lazar, S. Patel, P. Hwu, 2020, Journal for ImmunoTherapy of Cancer.

Chemical Castration of Melanoma Patients Does Not Increase the Frequency of Tumor-specific CD4 and CD8 T Cells After Peptide Vaccination

S. Patel, P. Hwu, G. Lizée, 2013, Journal of immunotherapy.

Prognostic factors for survival in melanoma patients with brain metastases

P. Hwu, Kevin B. Kim, A. Bedikian, 2011, Cancer.

Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies

Kevin B. Kim, B. Andrews, M. Nosrati, 2018, BMC Cancer.

Biomarkers of treatment benefit in a randomized phase II study of bevacizumab in combination with carboplatin and paclitaxel in metastatic melanoma patients (BEAM).

P. Hegde, Kevin B. Kim, S. O’Day, 2010 .

Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-&agr; in patients with metastatic melanoma

S. Patel, P. Hwu, S. Woodman, 2014, Melanoma research.

Complete clinical response to intralesional talimogene laherparepvec injection in a patient with recurrent, regionally advanced Merkel cell carcinoma

Kevin B. Kim, M. Kashani-Sabet, S. Leong, 2019, JAAD case reports.

Use of sargramostim as maintenance therapy in patients with stage IV melanoma at high risk for systemic recurrence.

Kevin B. Kim, W. Amos, Reena Hemrajani, 2007, Melanoma research.

Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy

P. Hwu, J. Homsi, Kevin B. Kim, 2012, Supportive Care in Cancer.

Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma

C. Berking, J. Berlin, P. Ascierto, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Case of vemurafenib‐induced Sweet's syndrome

Philip R. Cohen, Kevin B. Kim, Wei-Lien Wang, 2014, The Journal of dermatology.

Case Report of a Pregnancy During Ipilimumab Therapy

Kevin B. Kim, D. Minor, A. Mehta, 2017, Journal of global oncology.

Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type

S. Woodman, A. Lazar, Kevin B. Kim, 2009, Modern Pathology.

Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients

P. Hwu, J. Homsi, Kevin B. Kim, 2009, Melanoma research.

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Yu Shyr, Fei Ye, Donald Lawrence, 2012, The New England journal of medicine.

Pilot study of high‐dose, concurrent biochemotherapy for advanced melanoma

Kevin B. Kim, A. Bedikian, O. Eton, 2004, Cancer.

Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases

S. Patel, P. Hwu, Kevin B. Kim, 2012, Melanoma research.

Drug responses are conserved across patient-derived xenograft models of melanoma leading to identification of novel drug combination therapies

L. Soroceanu, A. Dar, Kevin B. Kim, 2019, British Journal of Cancer.

Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach.

M. Singer, N. Salomonis, S. Millis, 2021, The Journal of investigative dermatology.

Advances in targeted therapy for melanoma: a focus on MEK inhibition

Kevin B. Kim, A. Salama, 2014 .

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

M. Brown, R. Kurzrock, J. Infante, 2012, The Lancet.

A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma

C. Ng, P. Hwu, L. Camacho, 2012, Melanoma research.

Nuclear Receptor Coactivator NCOA3 Regulates UV Radiation–Induced DNA Damage and Melanoma Susceptibility

D. Schadendorf, L. Soroceanu, A. Dar, 2021, Cancer Research.

Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma

J. Kirkwood, Kevin B. Kim, M. Shi, 2011, Clinical Cancer Research.

BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling

Victor G Prieto, Manuela Baccarini, Lili Du, 2013, eLife.

Targeted Therapy in Melanoma

Kevin B. Kim, Sunil V. Patel, M. Davies, 2008 .

Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.

K. Flaherty, J. Sosman, A. Ribas, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Histological Features Associated With Vemurafenib-Induced Skin Toxicities: Examination of 141 Cutaneous Lesions Biopsied During Therapy

K. Tsai, M. Tetzlaff, D. Hong, 2014, The American Journal of dermatopathology.

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance

P. Stephens, R. Yelensky, M. Cronin, 2015, BMC Cancer.

Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates

G. Mills, D. Podoloff, A. Lazar, 2009, Molecular Cancer Therapeutics.

Spotlight on Clinical Response Activity of dasatinib against L 576 P KIT mutant melanoma : Molecular , cellular , and clinical correlates

G. Mills, D. Podoloff, A. Lazar, 2009 .

Dabrafenib for treatment of BRAF-mutant melanoma

Kevin B. Kim, G. Falchook, R. Kainthla, 2013, Pharmacogenomics and personalized medicine.

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

K. Flaherty, J. Sosman, A. Ribas, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients

Jeffrey E. Lee, V. Johnson, M. Ross, 2012, Clinical Cancer Research.

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.

P. Hwu, M. Sznol, P. Ott, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab in the treatment of advanced melanoma

Kevin B. Kim, 2015 .

Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer Therapy‐Melanoma questionnaire

M. Ross, D. Cella, J. Gershenwald, 2008, Cancer.

BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes

R. Kurzrock, F. Janku, A. Naing, 2011, PloS one.

Dabrafenib Therapy for Advanced Melanoma

Kevin B. Kim, Jaime Anderson, V. Trinh, 2014, The Annals of pharmacotherapy.

Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions

K. Tsai, M. Tetzlaff, D. Hong, 2014, International journal of dermatology.

PFS as a surrogate for overall survival in metastatic melanoma.

Kevin B. Kim, 2014, The Lancet. Oncology.

Drug safety evaluation of vemurafenib in the treatment of melanoma

K. Tsai, Kevin B. Kim, S. Nowroozi, 2013, Expert opinion on drug safety.

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.

D. Schadendorf, R. Dummer, A. Arance, 2013, The Lancet. Oncology.

Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma

S. Patel, Kevin B. Kim, 2012, Expert opinion on investigational drugs.

Recent Advances and Emerging Therapies In the Systemic Treatment of Metastatic Melanoma

Kevin B. Kim, J. Yorio, 2012 .

Cancer Therapy : Clinical Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma

J. Dancey, C. Ng, P. Fox, 2012 .

BRAF-targeted therapy for metastatic melanoma: rationale, clinical activity and safety

Kevin B. Kim, W. Hwu, V. Trinh, 2011 .

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

K. Flaherty, J. Sosman, I. Puzanov, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Factors That Determine the Long-Term Survival of Patients with Unresectable Metastatic Melanoma

P. Hwu, C. Warneke, Kevin B. Kim, 2008, Cancer investigation.

Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF‐mutated melanoma and other advanced malignancies

F. Meric-Bernstam, S. Patel, R. Kurzrock, 2018, Cancer.

Beyond BRAFV600: clinical mutation panel testing by next-generation sequencing in advanced melanoma

Jared C Malke, G. Mills, K. Aldape, 2014, The Journal of investigative dermatology.

Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies

P. Angenendt, F. Meric-Bernstam, R. Kurzrock, 2015, Oncotarget.

NRAS mutation status is an independent prognostic factor in metastatic melanoma

C. Ng, A. Lazar, P. Hwu, 2012, Cancer.

Treatment of KIT-mutated metastatic mucosal melanoma.

Kevin B. Kim, A. Alrwas, 2014, Chinese clinical oncology.

Arginine deprivation therapy for malignant melanoma

Jung-ki Yoon, Kevin B. Kim, L. Feun, 2012, Clinical pharmacology : advances and applications.

Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report

Kevin B. Kim, Ashok J. Kumar, M. Penas-Prado, 2015, BMC Cancer.

Dabrafenib for the treatment of melanoma

R. Amaria, Kevin B. Kim, 2014, Expert opinion on pharmacotherapy.

Phase I/II Study of a Cisplatin-Taxol-Dacarbazine Regimen in Metastatic Melanoma

P. Hwu, J. Homsi, Kevin B. Kim, 2009, American journal of clinical oncology.

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors

G. Curt, P. LoRusso, H. Burris, 2017, BMC Cancer.

Abstract B225: A phase I dose-escalation study of selumetinib in combination with docetaxel in patients with advanced solid tumors.

G. Curt, P. LoRusso, H. Burris, 2011 .

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

K. Flaherty, J. Sosman, Douglas B. Johnson, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression.

K. Flaherty, J. Sosman, A. Ribas, 2015, European journal of cancer.

MEK Inhibition in the Treatment of Advanced Melanoma

Kevin B. Kim, A. Salama, 2013, Current Oncology Reports.

The past, present, and future of melanoma therapy.

Kevin B. Kim, 2013, Oncology.

Trametinib (GSK1120212) in the treatment of melanoma

Kevin B. Kim, A. Salama, April K S Salama, 2013, Expert opinion on pharmacotherapy.

Current management of melanoma patients with nodal metastases

D. Reintgen, Kevin B. Kim, Dale Han, 2021, Clinical & experimental metastasis.

BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.

G. Linette, J. Sosman, Kevin B. Kim, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy

P. Hwu, Kevin B. Kim, A. Bedikian, 2010, Melanoma research.

Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs

Kevin B. Kim, T. Swe, 2018, Clinical & Experimental Metastasis.

Intratumoral talimogene laherparepvec therapy in melanoma.

Kevin B. Kim, 2015, Melanoma management.

Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma

J. Nemunaitis, R. Kurzrock, C. Andresen, 2012, Oncotarget.

Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).

R. Govindan, F. Hirsch, M. Brown, 2014, Clinical cancer research : an official journal of the American Association for Cancer Research.

Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma

A. Lazar, P. Hwu, J. Gershenwald, 2013, Cancer.

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.

D. Schadendorf, P. Ascierto, A. Ribas, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Critical Assessment of Adjuvant Radiotherapy for Inguinal Lymph Node Metastases from Melanoma

Jeffrey E. Lee, M. Ross, M. Ballo, 2004, Annals of Surgical Oncology.

Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma

J. Nemunaitis, R. Kurzrock, C. Andresen, 2015, Clinical Cancer Research.

GNAQmutation in a patient with metastatic mucosal melanoma

Dae Hyun Kim, S. Patel, Kevin B. Kim, 2014, BMC Cancer.

Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies

Kevin B. Kim, B. Andrews, M. Nosrati, 2018, BMC Cancer.

Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?

P. Hwu, C. Warneke, J. Homsi, 2011, Melanoma research.

Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment with Vemurafenib.

Philip R. Cohen, Kevin B. Kim, A. Bedikian, 2013, The Journal of clinical and aesthetic dermatology.

Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs

Kevin B. Kim, T. Swe, 2018, Clinical & Experimental Metastasis.

Biochemotherapy in patients with metastatic anorectal mucosal melanoma

Jeffrey E. Lee, L. Broemeling, M. Ross, 2004, Cancer.

Correction to: Intraoperative Imaging with a Portable Gamma Camera May Reduce the False-Negative Rate for Melanoma Sentinel Lymph Node Surgery

Kevin B. Kim, M. Kashani-Sabet, S. Leong, 2018, Annals of Surgical Oncology.

Intraoperative Imaging with a Portable Gamma Camera May Reduce the False-Negative Rate for Melanoma Sentinel Lymph Node Surgery

Kevin B. Kim, M. Kashani-Sabet, S. Leong, 2018, Annals of Surgical Oncology.

Interleukin-24 Gene Therapy for Melanoma

R. Ramesh, Kevin B. Kim, E. Grimm, 2010 .

Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma

A. D. Van den Abbeele, A. Giobbie-Hurder, F. Hodi, 2014, Cancer Imaging.

Phase 2 open-label study of weekly docosahexaenoic acid–paclitaxel in patients with metastatic uveal melanoma

P. Hwu, J. Homsi, Kevin B. Kim, 2010, Melanoma research.

GNAQ mutation in a patient with metastatic mucosal melanoma

S. Patel, Kevin B. Kim, C. Kim, 2014, BMC Cancer.

A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma

Kevin B. Kim, A. Bedikian, B. Lu, 2008, Melanoma research.

Impact of Clinical and Pathologic Features on Tumor-Infiltrating Lymphocyte Expansion from Surgically Excised Melanoma Metastases for Adoptive T-cell Therapy

Jeffrey E. Lee, M. Ross, A. Lucci, 2011, Clinical Cancer Research.

Reappraisal of the prognostic significance of mitotic rate supports its reincorporation into the melanoma staging system

K. Shannon, R. Scolyer, Kevin B. Kim, 2020, Cancer.

Predictive Factors for the Development of Brain Metastasis in Advanced Unresectable Metastatic Melanoma

P. Hwu, Caimiao Wei, J. Homsi, 2011, American journal of clinical oncology.

Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.

L. Garraway, X. Mu, R. Sullivan, 2016, JAMA oncology.

23LBA BEAM: A randomized phase II study evaluating the activity of BEvacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated Advanced Melanoma

G. Linette, J. Sosman, Kevin B. Kim, 2009 .

Making sense of the melanoma information tsunami.

Kevin B. Kim, J. Thompson, 2014, Melanoma management.

Pelvic computed tomography scans for surveillance in patients with primary melanoma in the head and neck

P. Hwu, J. Homsi, Kevin B. Kim, 2011, Melanoma research.

Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.

A. Ribas, L. Camacho, Kevin B. Kim, 2015, European journal of cancer.

Frequency of genetic homologous recombination (HR) alterations in metastatic cutaneous melanoma.

M. Singer, S. Millis, Kevin B. Kim, 2017 .

A randomized phase III trial of biochemotherapy versus interferon-&agr;-2b for adjuvant therapy in patients at high risk for melanoma recurrence

M. Ross, P. Hwu, J. Gershenwald, 2009, Melanoma research.

Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma

C. Ng, P. Hwu, L. Camacho, 2009, Cancer Chemotherapy and Pharmacology.

A Phase IB Trial of Intravenous INO-1001 Plus Oral Temozolomide in Subjects with Unresectable Stage-III or IV Melanoma

P. Hwu, J. Homsi, Kevin B. Kim, 2009, Cancer investigation.

6BA Early efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032

K. Flaherty, J. Sosman, A. Ribas, 2009 .

A phase II study of gefitinib in patients with metastatic melanoma

S. Patel, P. Hwu, Kevin B. Kim, 2011, Melanoma research.

A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors

G. Curt, P. LoRusso, H. Burris, 2017, Investigational New Drugs.

A phase II trial of arsenic trioxide in patients with metastatic melanoma

L. Camacho, Kevin B. Kim, A. Bedikian, 2005, Cancer.

BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma

A. Lazar, S. Patel, P. Hwu, 2012, Journal of cutaneous pathology.

Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma.

K. Flaherty, J. Sosman, I. Puzanov, 2012 .

Analysis of the effect of systemic corticosteroids on survival from tebentafusp in a phase 3 trial of metastatic uveal melanoma.

C. Watkins, P. Nathan, Kevin B. Kim, 2022, Journal of Clinical Oncology.

Correlation of immune response with clinical outcomes in melanoma patients receiving adjuvant therapy of pegylated interferon alpha-2b combined with gp100 peptide vaccine.

S. Patel, P. Hwu, Kevin B. Kim, 2014 .

Erratum to "Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies" [Oncotarget., 6 (2015) 12809-12821]

P. Angenendt, F. Meric-Bernstam, R. Kurzrock, 2015 .

Abstract 4588: Frequency and clinical characteristics ofc-METmutation in malignant melanoma

K. Aldape, D. Barron, Kevin B. Kim, 2012 .

Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results

R. Sullivan, K. Flaherty, J. Tabernero, 2014, Journal of Translational Medicine.

K. Flaherty, J. Tabernero, W. Miller, 2014, Journal of Translational Medicine.

Clinical characteristics of patients with non-V600 BRAF mutant melanomas.

A. Lazar, S. Patel, P. Hwu, 2014 .

Association between melanoma and renal-cell carcinoma for sequential diagnoses: A single-center retrospective study.

S. Patel, P. Hwu, Kevin B. Kim, 2018, Cancer epidemiology.

Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in BRAFV600E melanoma.

K. Flaherty, J. Sosman, A. Ribas, 2012 .

Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial.

K. Flaherty, J. Sosman, J. Infante, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Dabrafenib

Kevin B. Kim, G. Falchook, R. Kainthla, 2014, Reactions Weekly.

Targeted Therapy in Melanoma

Kevin B. Kim, Sunil V. Patel, M. Davies, 2008 .

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors

G. Curt, P. LoRusso, H. Burris, 2017, BMC Cancer.

SWOG S1221: A phase 1 dose escalation study co-targeting MAPK-dependent and MAPK-independent BRAF inhibitor resistance in BRAF mutant advanced solid tumors with dabrafenib, trametinib, and GSK2141795 (ClinicalTrials.gov NCT01902173).

A. Ribas, Kevin B. Kim, R. Gonzalez, 2017 .

Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis.

I. Lowy, K. Papadopoulos, J. Crown, 2023, Journal of Clinical Oncology.

Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.

G. Gibney, Kevin B. Kim, G. Long, 2023, Journal of Clinical Oncology.

Long-term safety and overall survival update for BREAK-2, a phase 2, single-arm, open-label study of dabrafenib in previously treated metastatic melanoma (NCT01153763).

D. Schadendorf, P. Ascierto, A. Ribas, 2014 .

Phase II study of the frontline combination of ipilimumab and temozolomide in patients with metastatic melanoma.

S. Patel, P. Hwu, Kevin B. Kim, 2012 .